1.
Renneville A, Ben Abdelali R, Chevret S, et al. Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. Oncotarget. 2014;5(4):916-32. doi:10.18632/oncotarget.1536.
1.
Nagy L, Kao HY, Chakravarti D, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell. 1997;89(3):373-80.
1.
Shaw AT, Winslow MM, Magendantz M, et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A. 2011;108(21):8773-8. doi:10.1073/pnas.1105941108.
1.
Yu M, Maden SK, Stachler M, et al. Subtypes of Barrett’s oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut. 2019;68(3):389-399. doi:10.1136/gutjnl-2017-314544.
1.
Sandoval GJ, Hahn WC. Going beyond genetics to discover cancer targets. Genome Biol. 2017;18(1):95. doi:10.1186/s13059-017-1238-7.
1.
Christian S, Merz C, Evans L, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. 2019;33(10):2403-2415. doi:10.1038/s41375-019-0461-5.
1.
Olive JF, Qin Y, DeCristo MJ, Laszewski T, Greathouse F, McAllister SS. Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies. PLoS One. 2018;13(6):e0198790. doi:10.1371/journal.pone.0198790.
1.
Ben-David U, Ha G, Tseng Y-Y, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49(11):1567-1575. doi:10.1038/ng.3967.
1.
Hinze L, Pfirrmann M, Karim S, et al. Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell. 2019;35(4):664-676.e7. doi:10.1016/j.ccell.2019.03.004.
1.
Alvarez MJ, Subramaniam PS, Tang LH, et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet. 2018;50(7):979-989. doi:10.1038/s41588-018-0138-4.